2. Inflammation/Immunology

Inflammation/Immunology (炎症/免疫)

Inflammation/Immunology

関連製品

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

製品番号 製品名 CAS 番号 純度 構造式
  • HY-P11205
    Cys-PKHB1 2378833-51-1 98%
    Cys-PKHB1 (Cys-txCD47) is a peptide conjugated to PKHB1, a CD47 agonist peptide and a thrombospondin-1 peptide mimic with antitumor effects. PKHB1 induces mitochondrial alterations, ROS generation, intracellular Ca+ accumulation, and calcium-dependent cell death in breast cancer cells. PKHB1 induces immune system activation in breast cancer cells through immunogenic cell death.
    Cys-PKHB1
  • HY-P11206
    Murine cardiac troponin I peptide 98%
    Murine cardiac troponin I peptide (Murine cardiac TnI peptide) is a murine cardiac troponin I (cTnI) peptide. Murine cardiac troponin I peptide can induce significant myocardial inflammation followed by fibrosis and heart failure with increased mortality in mice model. Murine cardiac troponin I peptide can be used for heart failure research.
    Murine cardiac troponin I peptide
  • HY-P11207
    NLS-CPP 1228086-59-6
    NLS-CPP is a nuclear localization signal (NLS)-cell-penetrating peptide, which contains the NLS of OCT6. NLS-CPP facilitates nuclear delivery. NLS-CPP can be used for chronic inflammatory diseases s research, such as metabolic-dysfunction-associated steatohepatitis (MASH) and osteoarthritis (OA).
    NLS-CPP
  • HY-P11208
    mNLS-CPP-WSTF
    mNLS-CPP-WSTF is a nuclear localization signal (NLS)-cell-penetrating peptide based on the mouse WSTF sequence. mNLS-CPP-WSTF significantly inhibits the GABARAP-WSTF interaction, WSTF degradation and inflammatory gene expression. mNLS-CPP-WSTF effectively attenuates chronic inflammation, liver fibrosis and cartilage damage in metabolic-dysfunction-associated steatohepatitis (MASH) and osteoarthritis (OA) mice model. mNLS-CPP-WSTF is promising for research of chronic inflammatory diseases such as MASH and OA.
    mNLS-CPP-WSTF
  • HY-P11210
    A68828 132309-52-5
    A68828 is an atrial natriuretic factor (ANF) analog. A68828 can improve renal function in an acute model of postischemic acute renal failure. A68828 can be studied in research on ischemic acute renal failure.
    A68828
  • HY-P11214
    Hydrostatin-TL1 2243975-43-9
    Hydrostatin-TL1 (H-TL1), a nine-amino-acid peptide, is a TNF-α antagonist. Hydrostatin-TL1 can be isolated from the venom gland of sea snake Hydrophis cyanocinctus. H-TL1 competitively inhibits the interaction between TNF-α/TNFR1 and attenuates the cytotoxicity and inflammation of TNF-α. Hydrostatin-TL1 can be used for TNF-α-associated inflammatory diseases, such as rheumatoid arthritis, osteoporosis and inflammatory bowel disease (IBD) research.
    Hydrostatin-TL1
  • HY-P11229
    GGGGSGGGGS 192805-56-4
    GGGGSGGGGS is a chimeric peptide composed of four peptides. GGGGSGGGGS can efficiently bind to small intestinal submucosa (SIS) membranes. GGGGSGGGGS can be used for research on infectious or inflammatory conditions.
    GGGGSGGGGS
  • HY-P11241
    oNCM
    oNCM is an antibacterial peptide. oNCM has good antibacterial activity, anti biofilm ability, anti-inflammatory effect, high stability, and low cytotoxicity. oNCM can be used for research on infectious or inflammatory conditions.
    oNCM
  • HY-P11250
    HVF18-a3-d 98%
    HVF18-a3-d is an antimicrobial peptide. HVF18-a3-d reduces NO production. HVF18-a3-d inhibits the production of TNF-α and IL-6, reduces ROS production, and suppresses the TLR4 signaling pathway, as well as LPS-induced phosphorylation of ERK, JNK, and p38 MAPK. HVF18-a3-d exhibits antimicrobial activity against a variety of bacteria by disrupting their outer and inner membranes. HVF18-a3-d protects mice from fatal septic shock induced by Acinetobacter baumannii resistant to Carbapenem. HVF18-a3-d shows anti-inflammatory and antioxidant effects.
    HVF18-a3-d
  • HY-P11253
    DOTA-Bn-CA-170
    DOTA-Bn-CA-170 is a molecular probe targeting the VISTA protein, with a Kd value of 0.124 nM. DOTA-Bn-CA-170 is formed by covalently linking the p-SCN-Bn-DOTA ligand with CA-170 (HY-101093). DOTA-Bn-CA-170 labeled with [68Ga]Ga successfully achieves specific and high-contrast PET imaging of VISTA expression in various tumor-bearing mouse models. DOTA-Bn-CA-170 can be used for the study of VISTA-targeted immunotherapy.
    DOTA-Bn-CA-170
  • HY-P11258
    UPG-108 3090686-88-4
    UPG-108, a peptide compound, is a non-competitive allosteric modulator of Urotensin II receptors (UTR). UPG-108 significantly enhances the efficacy of UTR agonists but reduces the potency of UTR agonists. UPG-111 efficiently induces calcium release and does not cause contraction of rat aortic rings without endothelial denudation. UPG-111 can be used to study various diseases related to the angiotensinergic system.
    UPG-108
  • HY-P11259
    UPG-111 3090687-02-5
    UPG-111 is a peptide compound that acts as a negative allosteric modulator of the Urotensin II receptor (UTR). UPG-111 exhibits a dual inhibitory effect on the vasoconstriction induced by UTR agonists - it reduces both the maximum response intensity and the sensitivity of the agonist. UPG-111 does not induce calcium release or cause contraction of the endothelium-deprived rat aortic rings. UPG-111 can be used for the study of various diseases related to the angiotensinergic system.
    UPG-111
  • HY-P11264
    Cyclic peptide P1-1 98%
    Cyclic peptide P1-1 is a high-potent GPR55 antagonist. Cyclic peptide P1-1 antagonizes GPR55 and suppresses collagen secretion. Cyclic peptide P1-1 reduces ROS production, attenuates ER stress, and inhibits mitochondria-associated Apoptosis. Cyclic peptide P1-1 inhibits the expression of α-SMA and COL1α. Cyclic peptide P1-1 ameliorates CCl4 (HY-Y0298)-induce and MCD-diet-induce acute liver inflammation and fibrosis.
    Cyclic peptide P1-1
  • HY-P11281
    GYGGGP(GPP)5GFOGER(GPP)5GPC 3063714-39-3
    GYGGGP(GPP)5GFOGER(GPP)5GPC is a type I collagen mimic that can bind to integrins and modify hydrogels.
    GYGGGP(GPP)5GFOGER(GPP)5GPC
  • HY-P11296
    LLVK 798540-36-0 98%
    LLVK is a selective IκB phosphorylation inhibitor. LLVK reduces LPS-induced pro-inflammatory cytokines (IL-1β, IL-6, TNF-α). LLVK is promising for research of inflammatory bowel disease and rheumatoid arthritis.
    LLVK
  • HY-P11298
    d-T101 peptide 2120397-85-3 98%
    d-T101 peptide, a human hormone-peptide, is a T1/ST2 receptor ligand. d-T101 peptide binds to the T1/ST2 receptor and activates caspases 8, 9 and 3 mediated apoptosis, together with activation of JNKinase and p38 MAPKinase. d-T101 peptide also changes Golgi structural with function loss and downregulation of the endoplasmic reticulum (ER) stress repair mechanism. d-T101 peptide has immunostimulatory and anticancer activity, selectively induces apoptosis in proliferating cancer cells and increases IL-2 and IFN-γ expression as well as the recruitment of NK cells and M1 macrophages to the tumor site.
    d-T101 peptide
  • HY-P11299
    EBNA-1 (386–405 aa) 3082858-70-3
    EBNA-1 (386-405 aa) is a cross-reactive viral antigen peptide. EBNA-1 (386-405 aa) has a high molecular similarity to GlialCAM (370-389 aa) and it induces the production of cross-reactive antibodies that recognize both EBV antigens and glial cells in the central nervous system, thereby triggering autoimmune responses. EBNA-1 (386-405 aa) can used for Epstein-Barr virus (EBV) infection and multiple sclerosis (MS) research.
    EBNA-1 (386–405 aa)
  • HY-P11304
    SFTI-KLK5
    SFTI-KLK5 is a KLL5 inhibitor with a Ki value of 5.1 nM.
    SFTI-KLK5
  • HY-P11305
    SFTI-KLK7
    SFTI-KLK7 is a KLK7 inhibitor, with Ki 0.14 nM.
    SFTI-KLK7
  • HY-P11340
    VMAPRTLFL 202657-61-2
    VMAPRTLFL is a 9-mer peptide derived from the signal peptide of HLA-G and can serve as a peptide ligand for HLA-E. VMAPRTLFL plays a crucial role in regulating the functions of adaptive natural killer (NK) cells. Specifically, VMAPRTLFL enriches FcεRγ- adaptive NK cells, upregulates the expression of CD25, and enhances their proliferative activity, antibody-dependent cellular cytotoxicity (ADCC), and IFN-γ release. VMAPRTLFL can be used in research related to human cytomegalovirus (HCMV) infection, transplant rejection, and pregnancy immunity.
    VMAPRTLFL
製品番号 製品名 / Synonyms Application Reactivity